Show simple item record

dc.contributor.authorIlik, M.K.
dc.contributor.authorIlik, F.
dc.date.accessioned2020-08-07T12:51:45Z
dc.date.available2020-08-07T12:51:45Z
dc.date.issued2019
dc.identifier10.5137/1019-5149.JTN.22604-18.2
dc.identifier.issn10195149 (ISSN)
dc.identifier.urihttp://hdl.handle.net/20.500.12498/2811
dc.description.abstractAIM: To evaluate the clinical outcomes of the retrogasserian opioid application in patients with type 1 trigeminal neuralgia. MATERIAL and METHODS: A total of 37 patients (12 male, 25 female; average age 56.2 ± 5.4 years) who were administered retrogasserian opioid due to type 1 trigeminal neuralgia between February 2012 and May 2015 were included in the study. A visual analogue scale was used to evaluate pain at the last preoperative and postoperative visits (median follow-up period: 13 months, mean follow-up period: 15.6 months). All parameters were analysed using Wilcoxon signed-rank and Mann-Whitney U tests, with p < 0.05 considered statistically significant. RESULTS: Visual analogue scale scores of all 37 patients were significantly improved in the postoperative period. The average visual analogue scale scores were 7.9 ± 0.62 preoperatively and 2.9 ± 0.5 postoperatively. All changes were statistically significant. CONCLUSION: Percutaneous retrogasserian opioid injection in type 1 trigeminal neuralgia is an effective and safe method of pain control. © 2019, Turkish Neurosurgical Society.
dc.language.isoEnglish
dc.publisherTurkish Neurosurgical Society
dc.sourceTurkish Neurosurgery
dc.titleEvaluation of the retrogasserian opioid application in the treatment of idiopathic trigeminal neuralgia
dc.typeArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record